Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Your Article Summary
See Latest ArticlesPrevalence and Risk Factors for Aminoglycoside Nephrotoxicity in Intensive Care Units
Antimicrobial Agents and Chemotherapy, 06/26/09
Oliveira JFP et al. - AKI was frequent among ICU patients receiving an aminoglycoside, and it was associated with a high rate of mortality. The presence of diabetes or hypotension and the use of other nephrotoxic drugs and iodinated contrast were independent risk factors for the development of aminoglycoside-associated nephrotoxicity.
Related Articles
Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors
European Journal of Cancer, 10/23/09
Relevance Score: 85%
What I tell my patients about contrast medium nephrotoxicity
British Journal of Renal Medicine, 10/27/09
Relevance Score: 82%
Long-Term Evaluation of Ifosfamide-Related Nephrotoxicity in Children
Journal of Clinical Oncology, 10/26/09
Relevance Score: 82%
Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells
American Journal of Physiology: Renal Physiology, 11/12/09
Relevance Score: 80%
Renal Dendritic Cells Ameliorate Nephrotoxic Acute Kidney Injury
Journal of the American Society of Nephrology, 11/04/09
Relevance Score: 80%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial
Gastroenterology, 12/08/09
Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis
Gastroenterology, 12/08/09
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease
Clinical and Experimental Gastroenterology, 12/08/09
Sponsor
Article Search
Sponsor
Sponsor